Acquired Company

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery on November 20, 2024.

Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Exscientia's pipeline of internal and partnered programmes demonstrates its ability to rapidly translate scientific concepts into precision-designed therapeutic candidates, with more than 25 projects advancing, including the first three AI-designed drug candidates to enter Phase 1 clinical trials. Exscientia has offices in Oxford, Vienna, Dundee, Miami, Boston, and Osaka. Show more

www.exscientia.ai

Research and Development in Biotechnology

Professional, Scientific, and Technical Services

Start AI Chat

Market Cap

0.00

52 Wk Range

$N/A - $N/A

Previous Close

$4.84

Open

$4.84

Volume

N/A

Day Range

$4.84 - $4.84

Enterprise Value

0.00

Cash

0.00

Avg Qtr Burn

N/A

Insider Ownership

25.90%

Institutional Own.

20.81%

Qtr Updated

09/30/24

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
EXS73565 (‘565) Details Cancer, B-cell malignancies, Chronic lymphocytic leukemia	Phase 1/2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
EXS74539 (‘539) Details Cancer	Phase 1/2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GTAEXS617 (CDK7 inhibitor) Details Solid tumor/s, Cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
EXS4318 (PKC-theta Inhibitor) Details Inflammatory disease	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
EXS21546 (A2A receptor antagonist) Details Cancer, Non-small cell lung carcinoma, Renal cell carcinoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.